Eli Lilly’s Alzheimer’s Drug Shows Greatest Benefit Yet

In a May 3 press release, Eli Lilly announced encouraging results from its latest study of its Alzheimer’s drug candidate, donanemab. In the Phase 3 study, which included more than…